Multicenter phase I study of erdafitinib (JNJ-42756493), oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors

Nom du journal : Clin Cancer Res

Année : 2019

Volume : 25

Page de départ : 4888

Page de fin : 4897

Auteurs: Zhong B, Moreno V, Calvo E, Mita A, Bahleda R, Italiano A, Tabernero J, Hierro C, Cervantes A, Chan N, Awad M, Govindan R, Spira A, Gonzalez M, Santiago-Walker A, Poggesi I, Parekh T, Xie H, Infante J,